US2005065107A1PendingUtilityA1

Plasmids suitable for IL-2 expression

65
Priority: Nov 28, 1994Filed: Oct 15, 2004Published: Mar 24, 2005
Est. expiryNov 28, 2014(expired)· nominal 20-yr term from priority
Inventors:Peter M. HobartMichal MargalithSuezanne ParkerShirin Khatibi
C07K 14/55C12N 2830/42A61P 35/00C12N 15/85A61K 48/00A61K 38/2013C12N 2840/20C07K 2319/02
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to plasmids suitable for IL-2 expression, particularly, human IL-2 expression, and related methods.

Claims

exact text as granted — not AI-modified
1 - 20 . (canceled)  
     
     
         21 . A method for treating cancer in a mammal comprising administering in vivo directly into a tumor of said mammal a formulation consisting of a DNA plasmid encoding a mature human interleukin 2 (IL-2) polypeptide and a pharmaceutically acceptable carrier.  
     
     
         22 . A method for treating cancer in a mammal comprising administering in vivo directly into a tumor of said mammal a formulation consisting essentially of a DNA plasmid encoding a mature human IL-2 polypeptide and a pharmaceutically acceptable carrier.  
     
     
         23 . The method of  claim 21 , wherein said mammal is a human.  
     
     
         24 . The method of  claim 22 , wherein said mammal is a human.  
     
     
         25 . The method of  claim 21 , wherein said DNA plasmid comprises: 
 (a) a first polynucleotide encoding said mature IL-2 polypeptide;    (b) a second polynucleotide encoding a peptide leader operably associated with said first polynucleotide, wherein said peptide leader directs secretion of said IL-2 polypeptide;    (c) a promoter operably associated with said first and second polynucleotides; and    (d) a transcription termination sequence operably associated with said first and second polynucleotides.    
     
     
         26 . The method of  claim 21 , wherein said DNA plasmid comprises nucleotides 1 to 2797 of SEQ ID NO:1.  
     
     
         27 . The method of  claim 21 , wherein said cancer is a melanoma.  
     
     
         28 . The method of  claim 21 , wherein said cancer is a renal cell adenocarcinoma.  
     
     
         29 . The method of  claim 22 , wherein said DNA plasmid comprises: 
 (a) a first polynucleotide encoding said mature IL-2 polypeptide;    (b) a second polynucleotide encoding a peptide leader operably associated with said first polynucleotide, wherein said peptide leader directs secretion of said IL-2 polypeptide;    (c) a promoter operably associated with said first and second polynucleotides; and    (d) a transcription termination sequence operably associated with said first and second polynucleotides.    
     
     
         30 . The method of  claim 22 , wherein said DNA plasmid comprises nucleotides 1 to 2797 of SEQ ID NO:1.  
     
     
         31 . The method of  claim 22 , wherein said cancer is a melanoma.  
     
     
         32 . The method of  claim 22 , wherein said cancer is a renal cell adenocarcinoma.  
     
     
         33 . The method of  claim 23 , wherein said DNA plasmid comprises: 
 (a) a first polynucleotide encoding said mature IL-2 polypeptide;    (b) a second polynucleotide encoding a peptide leader operably associated with said first polynucleotide, wherein said peptide leader directs secretion of said IL-2 polypeptide;    (c) a promoter operably associated with said first and second polynucleotides; and    (d) a transcription termination sequence operably associated with said first and second polynucleotides.    
     
     
         34 . The method of  claim 23 , wherein said DNA plasmid comprises nucleotides 1 to 2797 of SEQ ID NO:1.  
     
     
         35 . The method of  claim 23 , wherein said cancer is a melanoma.  
     
     
         36 . The method of  claim 23 , wherein said cancer is a renal cell adenocarcinoma.  
     
     
         37 . The method of  claim 24 , wherein said DNA plasmid comprises: 
 (a) a first polynucleotide encoding said mature IL-2 polypeptide;    (b) a second polynucleotide encoding a peptide leader operably associated with said first polynucleotide, wherein said peptide leader directs secretion of said IL-2 polypeptide;    (c) a promoter operably associated with said first and second polynucleotides; and    (d) a transcription termination sequence operably associated with said first and second polynucleotides.    
     
     
         38 . The method of  claim 24 , wherein said DNA plasmid comprises nucleotides 1 to 2797 of SEQ ID NO:1.  
     
     
         39 . The method of  claim 24 , wherein said cancer is a melanoma.  
     
     
         40 . The method of  claim 24 , wherein said cancer is a renal cell adenocarcinoma.

Join the waitlist — get patent alerts

Track US2005065107A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.